<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39507365</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-193X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Lancet regional health. Americas</Title><ISOAbbreviation>Lancet Reg Health Am</ISOAbbreviation></Journal><ArticleTitle>Clinical and functional assessment of SARS-CoV-2 sequelae among young marines - a panel study.</ArticleTitle><Pagination><StartPage>100909</StartPage><MedlinePgn>100909</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100909</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lana.2024.100909</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long-term SARS-CoV-2 adverse health outcomes are of significant concern, especially among young adults with the potential for the greatest long-term morbidity. We sought to assess and characterize these outcomes in a cohort of Marines.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used a cohort of US Marines from a previous longitudinal, prospective observational study of acute SARS-CoV-2, most of whom were enrolled prior to infection. A panel study was established to assess for post-acute sequelae of COVID-19 (PASC), defined as symptoms at least 4 weeks after symptom onset or diagnosis. Symptoms were assessed through questionnaires and validated quality of health metrics. Periodic US Marine Corps fitness testing metrics provided an additional standardized functional assessment and were compared to a pre-pandemic cohort.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Globally dispersed Marine participants (n&#xa0;=&#xa0;899) seen an average of 330 days following initial enrollment were predominately male (n&#xa0;=&#xa0;825, 91.7%), White (n&#xa0;=&#xa0;613, 71.6%) or Black (n&#xa0;=&#xa0;149, 17.4%) with a median age of 18 years (interquartile range: 18-19). Among 798 SARS-CoV-2 infected participants, 197 (24.7%) developed PASC. The most prevalent symptoms were loss of taste and/or smell (n&#xa0;=&#xa0;82; 41.6%), shortness of breath (n&#xa0;=&#xa0;74; 37.6%), and cough (n&#xa0;=&#xa0;45; 22.8%). Those with PASC had higher rates and severity of somatic (p&#xa0;&lt;&#xa0;0.0001), general depressive (p&#xa0;&lt;&#xa0;0.0001), and anxiety (p&#xa0;=&#xa0;0.005) symptoms. Compared to a historic cohort of Marines, participants with PASC scored worse on their physical fitness assessments due to slower run times (p&#xa0;=&#xa0;0.002). Those with PASC continued to have decreased physical performance one year after completing initial training.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">In this population of healthy young adult US Marines with mostly either asymptomatic or mild acute COVID-19, one fourth reported physical, cognitive, or psychiatric long-term sequelae of infection. The Marines affected with PASC showed evidence of long-term decrease in functional performance suggesting that SARS-CoV-2 infection may negatively affect health for a significant proportion of young adults.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Defense Health Agency and Defense Advanced Research Projects Agency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Chad K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Charmagne G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakubski</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulifard</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peifang</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marayag</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrone</LastName><ForeName>Amethyst</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunez-Hernandez</LastName><ForeName>Edgar O</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vangeti</LastName><ForeName>Sindhu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Yongchao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goforth</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sealfon</LastName><ForeName>Stuart C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letizia</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Am</MedlineTA><NlmUniqueID>9918232503006676</NlmUniqueID><ISSNLinking>2667-193X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>SS serves as a consultant, acting Chief Scientific Officer and Chairman of the Scientific Advisory Board for GNOMX which is working on a diagnostic test for Long COVID. He is a shareholder and receives stock options in GNOMX Corp for his roles.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>12</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>12</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39507365</ArticleId><ArticleId IdType="pmc">PMC11539644</ArticleId><ArticleId IdType="doi">10.1016/j.lana.2024.100909</ArticleId><ArticleId IdType="pii">S2667-193X(24)00236-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carfi A., Bernabei R., Landi F., for the Gemelli Against Covid Post Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J.R., et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C., Bruningk S.C., Hoch T., et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024;383(6680) doi: 10.1126/science.adg7942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: what do we know about "long covid"? BMJ. 2020;370 doi: 10.1136/bmj.m2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Long COVID: 3 years in. Lancet. 2023;401(10379):795. doi: 10.1016/S0140-6736(23)00493-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00493-2</ArticleId><ArticleId IdType="pmc">PMC9998094</ArticleId><ArticleId IdType="pubmed">36906338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Zhao H., Tebbutt S.J. A&#xa0;glimpse into long COVID and symptoms. Lancet Respir Med. 2022;10(9):e81. doi: 10.1016/S2213-600(22)00217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-600(22)00217-X</ArticleId><ArticleId IdType="pmc">PMC9187332</ArticleId><ArticleId IdType="pubmed">35697054</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld M.S., Peluso M.J., Kaveti P., et al. Inflammation during early post-acute COVID-19 is associated with reduced exercise capacity and Long COVID symptoms after 1 year. medRxiv. 2022 doi: 10.1101/2022.05.17.22275235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.17.22275235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. How common is long COVID? Why studies give different answers. Nature. 2022;606(7916):852&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao P., Peritz D.C., Systrom D., Lewine K., Cornwell W.K., 3rd, Hsu J.J. Orthostatic and exercise intolerance in recreational and competitive athletes with long COVID. JACC Case Rep. 2022;4(17):1119&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9450930</ArticleId><ArticleId IdType="pubmed">36090156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull J.H., Wootten M., Moghal M., et al. Clinical patterns, recovery time and prolonged impact of COVID-19 illness in international athletes: the UK experience. Br J Sports Med. 2022;56(1):4&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34340972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudzik M., Babicki M., Kapusta J., et al. Long-COVID clinical features and risk factors: a retrospective analysis of patients from the STOP-COVID registry of the PoLoCOV study. Viruses. 2022;14(8):1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415629</ArticleId><ArticleId IdType="pubmed">36016376</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan P., Deviaterikova A., Velichkovsky B.B., Kasatkin V. The impact of mild COVID-19 on executive functioning and mental health outcomes in young adults. Healthcare (Basel) 2022;10(10):1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9601355</ArticleId><ArticleId IdType="pubmed">36292338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizewski R.A., Sealfon R.S.G., Park S.W., et al. SARS-CoV-2 outbreak dynamics in an isolated US military recruit training center with rigorous prevention measures. Epidemiology. 2022;33(6):797&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9531985</ArticleId><ArticleId IdType="pubmed">35944149</ArticleId></ArticleIdList></Reference><Reference><Citation>Investing in the health and well-being of young adults committee on improving the health, safety, and well-being of young adults. Institute of Medicine; National Research Council; Washington, DC: 2015.</Citation></Reference><Reference><Citation>Kim Y., Bae S., Chang H.H., Kim S.W. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci Rep. 2023;13(1) doi: 10.1038/s41598-023-36995-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-36995-4</ArticleId><ArticleId IdType="pmc">PMC10336045</ArticleId><ArticleId IdType="pubmed">37433819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen I., Ekstrom S., Hallberg J., et al. Post COVID-19 symptoms are common, also among young adults in the general population. Sci Rep. 2023;13(1) doi: 10.1038/s41598-023-38315-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-38315-2</ArticleId><ArticleId IdType="pmc">PMC10338459</ArticleId><ArticleId IdType="pubmed">37438424</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Letizia A.G., Ge Y., Vangeti S., et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9(7):712&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049591</ArticleId><ArticleId IdType="pubmed">33865504</ArticleId></ArticleIdList></Reference><Reference><Citation>Menard S. Elsevier; Amsterdam: 2008. Handbook of longitudinal research: design, measurement, and analysis; pp. 30&#x2013;31.</Citation></Reference><Reference><Citation>Kroenke K., Spitzer R.L., Williams J.B. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K., Strine T.W., Spitzer R.L., Williams J.B., Berry J.T., Mokdad A.H. The PHQ-8 as a measure of current depression in the general population. J&#xa0;Affect Disord. 2009;114(1-3):163&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752852</ArticleId></ArticleIdList></Reference><Reference><Citation>Plummer F., Manea L., Trepel D., McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">26719105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapin B.R., Bena J.F., Walia H.K., Moul D.E. The Epworth sleepiness scale: validation of one-dimensional factor structure in a large clinical sample. J&#xa0;Clin Sleep Med. 2018;14(8):1293&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086944</ArticleId><ArticleId IdType="pubmed">30092893</ArticleId></ArticleIdList></Reference><Reference><Citation>Shattuck N.L., Matsangas P. Psychomotor vigilance performance predicted by Epworth Sleepiness Scale scores in an operational setting with the United States Navy. J&#xa0;Sleep Res. 2015;24(2):174&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">25273376</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns M.W. A&#xa0;new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">1798888</ArticleId></ArticleIdList></Reference><Reference><Citation>Marine Corps Order 6100.13A. Marine corps physical fitness and combat fitness tests (CFT/PFT). Department of the Navy. https://www.marines.mil/News/Publications/MCPEL/Electronic-Library-Display/Article/2524537/mco-610013a-wch-4/</Citation></Reference><Reference><Citation>Marine Corps Reference Publication 3-01A, Rifle marksmanship  . Department of the Navy; 2012. Publication control number: 144 000091 00.https://www.trngcmd.marines.mil/Portals/207/Docs/wtbn/MCRP%203-01A.pdf Available at:</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares-Schanoski A., Sauerwald N., Goforth C.W., et al. Asymptomatic SARS-CoV-2 infection is associated with higher levels of serum IL-17C, matrix metalloproteinase 10 and fibroblast growth factors than mild symptomatic COVID-19. Front Immunol. 2022;13 doi: 10.3389/fimmu.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022</ArticleId><ArticleId IdType="pmc">PMC9037090</ArticleId><ArticleId IdType="pubmed">35479098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox J. 2nd ed. Sage; 2008. Applied regression analysis and generalized linear models.</Citation></Reference><Reference><Citation>Fox J., Weisberg S. 2nd ed. Sage; 2011. An R companion to applied regression.</Citation></Reference><Reference><Citation>Hruby A., Lieberman H.R., Smith T.J. Symptoms of depression, anxiety, and post-traumatic stress disorder and their relationship to health-related behaviors in over 12,000 US military personnel: Bi-directional associations. J&#xa0;Affect Disord. 2021;283:84&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33524663</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I., Joseph P., Heerdt P.M., et al. Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing. Chest. 2022;161(1):54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354807</ArticleId><ArticleId IdType="pubmed">34389297</ArticleId></ArticleIdList></Reference><Reference><Citation>van Voorthuizen E.L., van Helvoort H.A.C., Peters J.B., van den Heuvel M.M., van den Borst B. Persistent exertional dyspnea and perceived exercise intolerance after mild COVID-19: a critical role for breathing dysregulation? Phys Ther. 2022;102(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384552</ArticleId><ArticleId IdType="pubmed">35900016</ArticleId></ArticleIdList></Reference><Reference><Citation>Baratto C., Caravita S., Faini A., et al. Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. J&#xa0;Appl Physiol (1985) 2021;130(5):1470&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143785</ArticleId><ArticleId IdType="pubmed">33764166</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao W., Miller C.M., Nair V.D., et al. A&#xa0;methylation clock model of mild SARS-CoV-2 infection provides insight into immune dysregulation. Mol Syst Biol. 2023;19(5) doi: 10.5252/msb.202211361.</Citation><ArticleIdList><ArticleId IdType="doi">10.5252/msb.202211361</ArticleId><ArticleId IdType="pmc">PMC10167476</ArticleId><ArticleId IdType="pubmed">36919946</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., W H.O. Clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.P. Estimating total morbidity burden of COVID-19: relative importance of death and disability. J&#xa0;Clin Epidemiol. 2022;142:54&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547965</ArticleId><ArticleId IdType="pubmed">34715312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>